



-JRW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket: ORLOW=1A

In re Application of: ) Conf. No.: 3666  
Seth ORLOW et al. ) Art Unit: 1615  
Appln. No.: 10/821,981 ) Examiner:  
Filed: April 12, 2004 ) Washington, D.C.  
For: COMPOUNDS STIMULATING ) October 27, 2004  
FORMATION AND FOR... )

INFORMATION DISCLOSURE STATEMENT [IDS]

Honorable Commissioner for Patents  
U.S. Patent and Trademark Office  
2011 South Clark Place  
Customer Window, Mail Stop Amendment  
Crystal Plaza Two, Lobby, Room 1B03  
Arlington, VA 22202

Sir:

This Information Disclosure Statement is submitted in accordance with 37 CFR §§1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.

[X] 1. This IDS should be considered, in accordance with 37 CFR §1.97, as it is filed:

(Check one of the boxes A-D)

[ ] A. within three months of the filing date of the above-identified national application or within three months of the entry into the national stage of the above-identified international application.

[X] B. before the mailing date of a first office action on the merits or before the mailing of a first Office action after the filing of a Request for Continued Examination under 37 CFR §1.114.

[X] 2. In accordance with 37 CFR §1.98, this IDS includes a list (e.g., form PTO-1449) of all patents, publications, or other information submitted for consideration by the office, either incorporated into this IDS or as an attachment hereto. A copy of each document listed is attached, except as explained below.

[X] 3. No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 and 68 in the preamble to the final rules; 1135 OG 13 at 20).

4. In accordance with 37 CFR §§1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in 37 CFR §1.56 (b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant(s) reserves the right to prove that the date of publication is in fact different.

Respectfully submitted,

BROWDY AND NEIMARK  
Attorneys for Applicant(s)

By:

  
Anne M. Kornbau  
Registration No. 25,884

AMK:srd  
624 Ninth Street, N.W., Suite 300  
Washington, D.C. 20001-5303  
Telephone: (202) 628-5197  
Facsimile: (202) 737-3528  
G:\BN\N\nyum\ORLOW 1A\pto\Ids 27 Oct 04.doc

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1

of 2

## Complete if Known

Application Number	10/821,981
Filing Date	April 12, 2004
First Named Inventor	Seth ORLOW et al.
Group Art Unit	1615
Examiner Name	-
Attorney Docket Number	ORLOW1A



## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
/C.B./	AA	CHIU, EASTER, et al., Postnatal Ocular Expression of Tyrosinase and Related Proteins: Disruption by the Pink-eyed Unstable ( <sup>p</sup> u) Mutation, March 19, 1993, pp. 301-305, Vol. 57	
/C.B./	AB	DURHAM-PIERRE, D., et al., African Origin of an intragenic deletion of the Human P Gene in Tyrosinase Positive Oculocutaneous Albinoism, NATURE GENETICS 7, June 1994, pp. 176-179	
/C.B./	AC	GAHL, WILLIAM A., et al., Melanosomal Tyrosine Transport in Normal and Pink-eyed Dilution Murine Melanocytes, PIGMENT CELL RESEARCH, June 9, 1995, pp. 229-233, Vol. 8	
/C.B./	AD	GARDNER, JOHN M., et al., The Mouse Pink-Eyed Dilution Gene: Association with Human Prader-Willi and Angelman Syndromes, SCIENCE 257, August 21, 1992, pp. 1121-1124	
/C.B./	AE	HEARING, VINCENT J., Invited Editorial: Unraveling the Melanocyte, AM. J. HUM. GENET. 52, 1993, pp. 1-7	
/C.B./	AF	IIDA, KOICHI, et al., Potent Inhibitors of Tyrosinase Activity and Melanin Biosynthesis from Rheum Officinale, Planta Med. 61, March 12, 1995, pp. 425-428, GEORGE THIEME STUTTGART, NEW YORK	
/C.B./	AG	KORNER, ANN, et al., Mammalian Tyrosinase Catalyzes Three Reactions in the Biosynthesis of Melanin, SCIENCE, September 17, 1982, pp. 1163-1165, Vol. 217	
/C.B./	AH	LAMOREUX, LYNN M., et al., The Pink-eyed Dilution Protein and The Eumelanin/Phaeomelanin Switch: In Support of a Unifying Hypothesis, PIGMENT CELL RESEARCH 8, September 4, 1995, pp. 263-270	
/C.B./	AI	LERNER, AARON BUNSEN, et al., Physiology Rev. 30, Biochemistry of Melanin Formation, January 1950, pp. 91-126, Vol. 30	
/C.B./	AJ	ORLOW, SETH J., et al., The Pink-Eyed Dilution Locus Controls the Biogenesis of Melanosomes and Levels of Melanosomal Proteins in the Eye, EXP. EYE RES., 1999, pp. 147-154, Vol. 68, Academic Press	
/C.B./	AK	ORLOW, SETH J., The Pigmentary System: Physiology and Pathophysiology 97, The Biogenesis of Melanosomes, pp. 97-106, Chapter 6, Oxford University Press, New York, Nordlund, et al., eds.	
/C.B./	AL	REISH, ORIT, et al., Tyrosine Inhibition Due to Interaction of Homocyst(e)ine with Copper: The Mechanism for Reversible Hypopigmentation in Homocystinuria Due to Cystathione $\beta$ -Synthase Deficiency, AM. J. HUM. GENET., April 11, 1995, pp. 127-132, Vol. 57	

Examiner Signature	/Courtney Brown/	Date Considered	11/27/2007
--------------------	------------------	-----------------	------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449A/PTO

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 3

3

**Complete if Known**

Application Number	10/821,981
Filing Date	April 12, 2004
First Named Inventor	Seth ORLOW et al.
Group Art Unit	1615
Examiner Name	—
Attorney Docket Number	ORLOW1A

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No.*	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
/C.B./	AM	ROSEMBLAT, SUSANA, et al., Melanosomal Defects in Melanocytes from Mice Lacking Expression of the Pink-Eyed Dilution Gene: Correction by Culture in the Presence of Excess Tyrosine, Experimental Cell Research 239, 1998, pp. 344-352	
/C.B./	AN	SVIDERSKAYA, ELENA V., et al., Complementation of hypopigmentation in p-Mutant (pink-Eyed Dilution) Mouse Human P cDNA, and Defective Complementation by OCA2 Mutant Sequences, THE JOURNAL OF INVESTIGATIVE DERMATOLOGY 108, January 1997, pp. 30-34	
/C.B./	AO	TASAKA, KENJI, et al. Effects of Certain Resorcinol Derivatives on the Tyrosinase Activity and the Growth of Melanoma Cells, Meth Find. Exp. Clin. Pharmaco. 20, 1998, pp. 99-109, Press Science, JAPAN	

Examiner Signature	/Courtney Brown/	Date Considered	11/27/2007
--------------------	------------------	-----------------	------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.